Physician profile
Terry Hostler
NPI 1982656625
$7,070.14
in general payments reported to CMS, 2019-2025
49 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,144 · 2020: $1,223 · 2021: $2,064 · 2022: $2,508 · 2023: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $131.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,030.86 | 2019-2022 | |
| Abbvie INC. | $559.06 | 2020-2022 | |
| Ucb, INC. | $517.65 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $511.36 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $436.47 | 2019-2023 | Austedo |
| Genzyme Corporation | $405.73 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $387.84 | 2022 | |
| Celgene Corporation | $311.39 | 2021-2022 | |
| Biogen, INC. | $224.39 | 2019-2022 | |
| Neurelis, INC. | $210.02 | 2020-2022 | |
| Lilly USA, LLC | $205.64 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $179.29 | 2022 | |
| Alexion Pharmaceuticals, INC. | $147.58 | 2019-2022 | |
| Allergan, INC. | $145.69 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $143.41 | 2020-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Hostler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.